Status:
ACTIVE_NOT_RECRUITING
Combined Injectable Treatment for HIV and OUD
Lead Sponsor:
Rhode Island Hospital
Conditions:
Human Immunodeficiency Virus
Opioid Use Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is study seeks to evaluate perspectives of a combined injectable treatment for HIV and OUD. Specifically, with the development of new long-acting medications such as cabotegravir co-administered ...
Detailed Description
Treatment services for HIV and OUD have historically been delivered across multiple settings leading to fragmented and uncoordinated care. Models of behavior change suggest that addressing multiple he...
Eligibility Criteria
Inclusion
- 18-65 years of age
- HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay
- Current diagnosis of OUD according to DSM-5
- Able to understand and speak English and to provide written and verbal informed consent
Exclusion
- Currently pregnant, breastfeeding, planning to become pregnant or breastfeed during the study period
- Coinfection of Hepatitis B or plans to get treated for Hepatitis C during the study period
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05991622
Start Date
April 1 2022
End Date
February 28 2026
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rhode Island Hospital
Providence, Rhode Island, United States, 02903